Video

Dr. Padrón on Biosignatures Found from a Phase 2 Study in Pancreatic Cancer

Lacey J. Padrón, PhD, discusses biosignatures found in a phase 2 study in pancreatic cancer.

Lacey J. Padrón, PhD, vice president, Informatics, Parker Cancer Institute for Immunotherapy, discusses biosignatures found in a phase 2 study (NCT03214250) in pancreatic cancer.

In this open-label, multicenter trial, oncologists examined the efficacy of gemcitabine and nab-paclitaxel plus sotigalimab (Apexigen; formerly APX 005M) and/or nivolumab (Opdivo) in patients with metastatic pancreatic adenocarcinoma.

The study revealed biomarkers of response, particularly to the sotigalimab/chemotherapy and nivolumab/chemotherapy combinations, Padrón explains. Moreover, in the patients’ blood and tumor at baseline, investigators found signals that correlated with longer survival, Padrón adds.

Those biosignature were distinct for the 2 combinations, and they related closely to the mechanisms of action of sotigalimab and nivolumab, respectively, Padrón concludes.

Related Videos
Benjamin Garmezy, MD, assistant director, Genitourinary Research, Sarah Cannon Research Institute
Howard S. Hochster, MD, FACP,
John H. Strickler, MD
Brandon G. Smaglo, MD, FACP
Cedric Pobel, MD
Ruth M. O’Regan, MD
Michael R. Grunwald, MD, FACP
Peter Forsyth, MD
John N. Allan, MD
Dr Dorritie on the Clinical Implications of the 5-Year Follow-Up Data From CAPTIVATE in CLL/SLL